logo-loader
Aggreko

Aggreko weak as Barclays cuts rating to ‘equal-weight’ from ‘overweight’, thinks stock now looks fairly valued

Barclays analysts said: “As the valuation has recovered from what we considered excessively depressed levels earlier in the year we now believe it fairly reflects the opportunities and risks”

Aggreko power plant
They also cut their target price for Aggreko to 760p from 830p, with the shares currently trading at 779.60p each

Barclays put the boot into Aggreko PLC (LON:AGK) on Thursday, downgrading its rating to ‘equal-weight’ from ‘overweight’ as it thinks the stock now looks fairly valued.

The bank’s analysts also cut their target price for the FTSE 250-listed temporary power provider to 760p from 830p, with the shares trading at 779.60p in late morning trading.

READ: Aggreko reports trading in line with expectations as Winter Olympics and Ryder Cup lift revenues

In a note to clients, Barclays analysts said the investment case for Aggreko and achievement of management's targets depends on “a manageable decline in the Utility business with the Rental and Industrial segments able to compensate.”

They added: “Despite a relatively reassuring third-quarter trading update, we feel the ongoing weakness in the Utility business and more general concerns of slower global economic growth could make it harder to progress as expected in 2019 and 2020.”

The analysts continued: “As the valuation has recovered from what we considered excessively depressed levels earlier in the year we now believe it fairly reflects the opportunities and risks.”

They said they only made small changes to profit forecasts for Aggreko, but a tax-induced reduction to their earnings per share estimates and the recent de-rating of the peer group leads it to cut its target and therefore downgrade its rating.

Quick facts: Aggreko

Price: £7.97

Market: LSE
Market Cap: £2.04 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Scancell back in the clinic with a phase II trial of its...

Scancell Holdings PLC's (LON:SCLP) Cliff Holloway tells Proactive London's Andrew Scott they've begun the UK arm of the phase II trial of its flagship skin cancer treatment. The trial is testing the safety and efficacy of SCIB1 in metastatic melanoma patients who are also receiving Merck’s...

8 hours, 2 minutes ago

2 min read